Slideshow

Three New Treatments for Osteoarthritis: Updates From ACR 2018

Late-breaking abstracts presented at ACR 2018 detail 3 promising options: a novel non-opioid analgesic and 2 disease-modifying OA drugs.

References1. Schnitzer TJ, Easton R, Pang S, et al. Efficacy and Safety of Subcutaneous Tanezumab for the Treatment of Osteoarthritis of the Hip or Knee [Abstract L20]. Arthritis Rheumatol. 2018;70(suppl 10). Accessed October 26, 2018.2. McGuire D, Segal N, Metyas S, et al. Intra-Articular TPX-100 in Knee Osteoarthritis: Robust Functional Response at 6 and 12 Months Is Associated with Increased Tibiofemoral Cartilage Thickness [Abstract L16]. Arthritis Rheumatol. 2018;70(suppl 10). Accessed October 26, 2018.3. Yazici Y, McAlindon TE, Gibofsky A, et al. Efficacy and Safety from a Phase 2b Trial of SM04690, a Novel, Intra-Articular, Wnt Pathway Inhibitor for the Treatment of Osteoarthritis of the Knee [Abstract L03]. Arthritis Rheumatol. 2018;70(suppl 10). Accessed October 26, 2018.This information is brought to you by Rheumatology Network and is not sponsored by, nor a part of, the American College of Rheumatology.

Related Videos
Considering Viral Infections in Patients With Rheumatic Disease With Leonard Calabrese, DO
Leonard H. Calabrese, DO, Professor of Medicine and Vice Chair, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University
Alvin Wells, MD, PhD: Making Informed Treatment Decisions With New Testing Strategies
Alvin Wells, MD, PhD
Upcoming Research in PsA, AxSpa, with Philip Mease, MD
Philip Mease, MD, Clinical Professor, University of Washington School of Medicine and Director, Rheumatology Research, Swedish Medical Center
Signs and Symptoms of Connective Tissue Disease
Connective Tissue Disease Brings Dermatology & Rheumatology Together
© 2024 MJH Life Sciences

All rights reserved.